Topiramate (lithium)

Topiramate (lithium)

• CAS Number: 488127-53-3
• UNSPSC Description: Topiramate (McN 4853) lithium is a broad-spectrum antiepileptic agent. Topiramate lithium is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase[1][2][3].
• Target Antigen: Calcium Channel; Carbonic Anhydrase; GABA Receptor; iGluR; Potassium Channel; Sodium Channel
• Type: Reference compound
• Related Pathways: Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling
• Applications: Neuroscience-Neuromodulation
• Field of Research: Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/topiramate-lithium.html
• Solubility: 10 mM in DMSO
• Smiles: NS(OC[C@]1(OC(C)(C)O2)[C@@H]2[C@H](OC(C)(C)O3)[C@H]3CO1)(=O)=O.[Li]
• Molecular Weight: 346.30
• References & Citations: [1]Kaminski RM, et al. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004 Jun;46(8):1097-104.|[2]Lyseng-Williamson KA, et al. Topiramate: a review of its use in the treatment of epilepsy. Drugs. 2007;67(15):2231-56.|[3]Nakamura J, et al. Target pharmacology of topiramate, a new antiepileptic drug. Nihon Yakurigaku Zasshi. 2000 Jan;115(1):53-7.
• Shipping Conditions: Room temperature
• Clinical Information: Launched